The Potential Roles of Epigallocatechin-3-Gallate in the Treatment of Ovarian Cancer: Current State of Knowledge.
Sabrina BimonteMarco CascellaPublished in: Drug design, development and therapy (2020)
Ovarian cancer represents the principal leading cause of women dying in the world. The first standard of care involved surgical resection followed by chemotherapy with taxane and platinum, mainly connected with cytotoxic chemotherapies causing diverse severe side effects. Unfortunately, recurrence represents a significant problem, and finally, patients develop resistance to cytotoxic chemotherapy. Other alternative treatments had been developed so far to reduce side effects; however, the outcomes are yet not empowering. Current shreds of evidence showed that epigallocatechin-3-gallate (EGCG) possesses an anticancer effect on ovarian carcinoma, mainly through the inhibition of different genetic signaling pathways which are closely linked with tumorigenesis. This review recapitulates these findings and highlights the roles of EGCG for the chemoprevention and treatment of ovarian cancer.
Keyphrases
- healthcare
- palliative care
- end stage renal disease
- signaling pathway
- chronic kidney disease
- newly diagnosed
- type diabetes
- ejection fraction
- oxidative stress
- prognostic factors
- pregnant women
- early onset
- risk assessment
- radiation therapy
- genome wide
- adipose tissue
- cell proliferation
- climate change
- induced apoptosis
- breast cancer risk
- smoking cessation
- health insurance